Use of JAK Inhibitors and Systemic Treatments for Atopic Dermatitis

Author(s):

Targeted agents, including JAK inhibitors, are increasingly used in atopic dermatitis management, reflecting their growing acceptance in clinical practice.
JAK inhibitors are considered for patients with moderate to severe atopic dermatitis, especially when rapid symptom control is required.
Clinicians assess JAKi versus biologics based on efficacy, safety, and patient-specific factors, tailoring treatment to individual needs.
Ideal candidates for JAK inhibitors are those unresponsive to topical treatments or biologics, or when other systemic therapies are unsuitable.

Dermatologists outline the role of targeted therapies and JAK inhibitors in the treatment of patients with atopic dermatitis.

EP: 1.Heterogenous Presentation of Atopic Dermatitis

Video content above is prompted by the following:

How widely are clinicians using targeted agents that have become available over the last few years?
Where do you place JAKi vs biologics in the treatment of atopic dermatitis?
When during patient’s treatment journey would you recommend use of JAK inhibitors to your patients?
Who is an ideal candidate for JAKi use in atopic dermatitis?